If you missed the press release and the big news yesterday, let’s get you caught up! Sanofi US announced via press release on February 23, 2016 that their agreement with kaléo will terminate sometime this year and all rights will be returned to kaléo. First I need to give you some background, kaléo pharmaceutical is spelled with a lower case k and is pronounced kah-léh-o. This pharmaceutical was formerly known as Intellject, the company founded by Auvi-Q® creators Eric and Evan Edwards, who are still at the helm of kaléo. Basically, the Auvi-Q® is coming home.
BUT…what does this mean? Is the Auvi-Q® dead and to never return to our anxious hands? Will the Edwards boys call it a day and not produce it? I doubt it and I must note that I am a girl who is all about the glass being half full. Immediately after the announcement the internet lit up with concerns and questions. I realized many of us did not get past the headlines before panic set in as we grieved the thought that theAuvi-Q® found its final resting place. The reality is that the Auvi-Q® is not dead until someone buries it.
Allergic Living Magazine immediately reached out and posted a short article, “Auvi-Q® Rights to Be Returned to Developer Under Deal with Sanofi,” highlighting a statement provided to them from Mark Herzog, Vice President of Corporate Affairs. After reading this piece, hope settled in that this return of rights might be a very good thing. Only time will tell and I will continue to hold onto my half full glass of soy milk.
The Urban Dictionary defines kaléo as “someone who is independent and likes to do what he feels like and is awesome at it”. kaléo was also defined as Badass-think this term was pretty darn accurate of how those Edwards boys must feel about their product.
Disclaimer: You might have seen this coming: I’m biased about Allergic Living Magazine since I’m their Product Review Editor and am a huge fan of their work. It just is. I also think the Edwards are pretty darn kaléo with their Auvi-Q® vision conceived in their teen years.
I hope your glass remains half full of hope that the Auvi-Q® return home will bring good things our way.
Related Posts
You may be interested in these posts from the same category.
One of the hardest things I find about managing both life threatening food allergies and asthma is talking to others. I hate to be the one that might be perceived as demanding, pushing or for asking too much. What I now know, fourteen years later, is that honest, clear information presented with kindness works!..
Fingers crossed this all works out! I am optimistic too about the return.
I crossed my toes too
Love this update, and thanks for keeping us up to date!
Hoping for a good outcome!
Me too! I can’t wait for it to come back and mis-fire the correct dose of epinephrine! It would be so exciting to see if my anaphylaxis will kill me!
Here’s the deal Henry, until that is proven, I only can speak about what is vetted. Also, just like with car manufacturers, companies address the issue and either make the correction or discontinue. I do hope that you are carrying two epinephrine auto-injectors and are prepared for anaphylaxis. Hopefully, you’ll never need your rescue meds.
So many factors figure into a company’s decision to invest further in a pharma product, particularly an injectable in a life/death emergency. What information does Sanofi have? Is the product design going to inherently always give a small but unacceptable fail rate? Or is the market anticipating too many generic entrants? Did the talking design not give enough advantage to draw market share? Or does Sanofi just have better uses for its investment capital than this? I think one of the former. Darn. Great concept.